Paradigm is developing disruptive technology for BSL 3/4 infectious agents, such as Ebola and novel treatments for immune mediated diseases. Paradigm is at the cutting edge of developing these treatments, but the sensitive nature of co-developing intellectual property prevents full disclosure on a “public domain” website. For accredited investors only, the following information is available on the Science Vest website: Pitch deck, Term Sheet, Team information, executive summary, FAQ and budget from 2016-2018.